US-based Dexcom has opened a new manufacturing and office facility in Athenry, Ireland, marking a major expansion in advanced manufacturing infrastructure with implications for facilities management in regulated environments.

Drug Delivery Business reported that the company invested $325m (€300m) in the development, with construction completed over a 25-month programme following ground-breaking in January 2024.

The facility represents Dexcom’s first manufacturing site outside the US and is expected to create more than 1,000 jobs, positioning it as one of the largest private sector investments in the west of Ireland.

The plant will manufacture Dexcom’s real-time continuous glucose monitoring systems, including its latest-generation G7 devices, requiring high-specification operational environments and ongoing facilities management support.

The company stated: “Our new home is officially open and it’s already buzzing with energy.”

It added: “This is more than just a factory, it’s a place where careers grow, people unite with a shared commitment to improving the lives of those living with diabetes worldwide, and where meaningful impact is made every single day.”

The development adds to Ireland’s growing medtech cluster, following recent manufacturing investments by global healthcare companies expanding production capacity in the region.

For facilities management providers, the project highlights increasing demand for specialised services in cleanroom operations, compliance-driven maintenance and energy-efficient building management across life sciences manufacturing sites.

The opening reinforces Ireland’s position as a strategic hub for high-value manufacturing, with ongoing requirements for integrated facilities services to support operational continuity and regulatory standards.

Follow the full details into Dexcom’s €300m Athenry facility, including construction timeline, manufacturing capabilities, and its impact on Ireland’s medtech infrastructure and facilities management requirements.